RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Immunovia AB (publ) Liabilities 2024

Immunovia AB (publ) Liabilities

31.69 M SEK

Immunovia AB (publ) Dividend yield

Ticker

IMMNOV.ST

ISIN

SE0006091997

WKN

A2AG0F

In 2024, Immunovia AB (publ)'s total liabilities amounted to 31.69 M SEK, a -44.19% difference from the 56.79 M SEK total liabilities in the previous year.

Immunovia AB (publ) Aktienanalyse

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a leading company in cancer diagnostics based in Lund, Sweden. Founded in 2007 by a group of scientists and entrepreneurs, the company specializes in the development, production, and marketing of diagnostic tests. Immunovia aims to develop innovative and reliable methods for early cancer detection to improve the progress and quality of life for cancer patients. The company's business model is based on research and development of state-of-the-art diagnostic tests, which are distributed worldwide through a network of partners. Immunovia collaborates closely with academic institutions, medical centers, and hospitals to promote research activities and conduct clinical studies. The company's goal is to develop biomarker-based tests for early cancer detection to increase patient survival rates. Immunovia operates in various fields, including pancreatic cancer diagnosis, colorectal cancer diagnosis, lupus diagnosis, and general cancer diagnostics. The company has developed products based on its diagnostic tests, such as the IMMray™ PanCan-d Test for pancreatic cancer diagnosis, IMMray™ Colon Test for colorectal cancer diagnosis, IMMray™ Lupus Test for lupus diagnosis, and IMMray™ Cancer-Screening Test for general cancer diagnostics. Immunovia actively collaborates with various partners, including strategic partnerships with leading biotechnology and pharmaceutical actors, to develop advanced diagnostic products. The company also has a strong financial base to fund its research activities and clinical studies. Overall, Immunovia is dedicated to developing innovative diagnostic tests for early cancer detection and is considered one of the leading players in the cancer diagnostics industry. Immunovia AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Immunovia AB (publ)'s Liabilities

Immunovia AB (publ)'s liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immunovia AB (publ)'s financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Immunovia AB (publ)'s liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Immunovia AB (publ)'s total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Immunovia AB (publ)’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Immunovia AB (publ) Stock

What is the level of liabilities of Immunovia AB (publ) this year?

Immunovia AB (publ) has a debt balance of 31.69 M SEK this year.

What were the liabilities of Immunovia AB (publ) compared to the previous year?

The liabilities of Immunovia AB (publ) have increased by -44.19% dropped compared to the previous year.

What are the consequences of high debt for investors of Immunovia AB (publ)?

High liabilities can pose a risk for investors of Immunovia AB (publ), as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Immunovia AB (publ)?

Low liabilities mean that Immunovia AB (publ) has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Immunovia AB (publ) affect the company?

An increase in liabilities of Immunovia AB (publ) can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Immunovia AB (publ) affect the company?

A decrease in the liabilities of Immunovia AB (publ) can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Immunovia AB (publ)?

Some factors that can influence the liabilities of Immunovia AB (publ) include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Immunovia AB (publ) so important for investors?

The liabilities of Immunovia AB (publ) are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Immunovia AB (publ) take to modify the liabilities?

To change its liabilities, Immunovia AB (publ) can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Immunovia AB (publ) pay?

Over the past 12 months, Immunovia AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunovia AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Immunovia AB (publ)?

The current dividend yield of Immunovia AB (publ) is .

When does Immunovia AB (publ) pay dividends?

Immunovia AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunovia AB (publ)?

Immunovia AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Immunovia AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunovia AB (publ) located?

Immunovia AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunovia AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunovia AB (publ) from 5/14/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/14/2024.

When did Immunovia AB (publ) pay the last dividend?

The last dividend was paid out on 5/14/2024.

What was the dividend of Immunovia AB (publ) in the year 2023?

In the year 2023, Immunovia AB (publ) distributed 0 SEK as dividends.

In which currency does Immunovia AB (publ) pay out the dividend?

The dividends of Immunovia AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunovia AB (publ)

Our stock analysis for Immunovia AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunovia AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.